We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biomarker Found for Heart Failure

By HospiMedica staff writers
Posted on 31 Aug 2005
Scientists have discovered an enzyme in the blood that could be a potential marker for heart failure, according to a new study reported in the July 29, 2005, online edition of the European Heart Journal.

In the study, the scientists compared tissue samples from a group of 24 patients with heart failure in need of transplants with tissue samples from 58 patients who were not sick but had various stages of left ventricular malfunction. More...
The results showed that the sicker patients had higher levels of an enzyme called beta-adrenergic kinase (ßARK1), or GRK2.

"We can track levels of this kinase with a simple blood test,” said Walter Koch, Ph.D., professor of medicine and director of the Center for Translational Medicine at Jefferson Medical College (Philadelphia, PA, USA), who led the team of scientists.” It appears consistent with the numerous animal studies we have done. When GRK2 is elevated in the blood, patients have more severe heart failure. It's a potential biomarker for heart failure.”

Animal studies have shown that the expression of GRK2 appears to be regulated by hormones called catecholamines, which include norepinephrine and epinephrine. These are message-carrying neurotransmitters in the sympathetic nervous system. In heart failure, this system is in overdrive, and levels of these hormones are high. In congestive heart failure, the beta-adrenergic receptor system fails to work properly. One function of GRK2 is to turn off beta-adrenergic receptors.

"In heart failure, beta adrenergic receptor density is decreased, ßARK is increased, and both together cause dysfunctional beta receptor signaling,” added Dr. Koch. "A failing heart then has little capacity to respond to exercise or stress because there are fewer receptors, and remaining receptors are more or less turned off.”


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.